Leerink Partnrs Comments on Teladoc Health Q1 Earnings

Teladoc Health, Inc. (NYSE:TDOC - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Teladoc Health in a note issued to investors on Wednesday, October 30th. Leerink Partnrs analyst M. Cherny expects that the health services provider will earn ($0.31) per share for the quarter. The consensus estimate for Teladoc Health's current full-year earnings is ($1.18) per share. Leerink Partnrs also issued estimates for Teladoc Health's Q2 2025 earnings at ($0.26) EPS and Q3 2025 earnings at ($0.29) EPS.

A number of other brokerages have also recently issued reports on TDOC. Barclays increased their target price on Teladoc Health from $10.00 to $12.00 and gave the stock an "overweight" rating in a report on Thursday. Deutsche Bank Aktiengesellschaft cut their price objective on Teladoc Health from $15.00 to $10.00 and set a "hold" rating for the company in a report on Friday, August 2nd. DA Davidson lowered their target price on shares of Teladoc Health from $12.00 to $8.00 and set a "neutral" rating on the stock in a report on Thursday, August 1st. Cantor Fitzgerald reissued an "overweight" rating and set a $10.00 price target on shares of Teladoc Health in a report on Tuesday, August 20th. Finally, Canaccord Genuity Group decreased their price objective on shares of Teladoc Health from $25.00 to $17.00 and set a "buy" rating on the stock in a research note on Thursday, August 1st. Fourteen equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $11.86.

Teladoc Health Price Performance

NYSE:TDOC traded up $0.07 during mid-day trading on Friday, hitting $9.07. The company's stock had a trading volume of 3,863,335 shares, compared to its average volume of 5,462,638. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -1.55 and a beta of 0.91. The company has a current ratio of 1.66, a quick ratio of 1.62 and a debt-to-equity ratio of 0.66. Teladoc Health has a fifty-two week low of $6.76 and a fifty-two week high of $22.54. The stock has a fifty day moving average of $8.41 and a 200-day moving average of $9.72.

Teladoc Health (NYSE:TDOC - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.10. The firm had revenue of $640.51 million for the quarter, compared to analyst estimates of $630.50 million. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 9.40%.

Insider Activity at Teladoc Health

In other Teladoc Health news, Director Thomas Mckinley purchased 4,000 shares of the stock in a transaction dated Thursday, September 12th. The stock was bought at an average price of $7.69 per share, for a total transaction of $30,760.00. Following the transaction, the director now directly owns 39,077 shares in the company, valued at $300,502.13. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Thomas Mckinley purchased 4,000 shares of Teladoc Health stock in a transaction dated Thursday, September 12th. The shares were acquired at an average cost of $7.69 per share, for a total transaction of $30,760.00. Following the transaction, the director now directly owns 39,077 shares of the company's stock, valued at approximately $300,502.13. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CMO Stephany Verstraete sold 15,000 shares of Teladoc Health stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $7.60, for a total value of $114,000.00. Following the sale, the chief marketing officer now directly owns 45,158 shares of the company's stock, valued at approximately $343,200.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 36,588 shares of company stock worth $268,831 over the last 90 days. Insiders own 0.95% of the company's stock.

Institutional Trading of Teladoc Health

A number of hedge funds have recently modified their holdings of TDOC. Signaturefd LLC raised its stake in Teladoc Health by 148.7% during the 2nd quarter. Signaturefd LLC now owns 2,868 shares of the health services provider's stock worth $28,000 after buying an additional 1,715 shares during the period. International Assets Investment Management LLC bought a new position in shares of Teladoc Health during the 2nd quarter valued at about $29,000. Blue Trust Inc. lifted its holdings in shares of Teladoc Health by 84.5% during the 3rd quarter. Blue Trust Inc. now owns 4,048 shares of the health services provider's stock valued at $40,000 after purchasing an additional 1,854 shares in the last quarter. Doheny Asset Management CA acquired a new position in shares of Teladoc Health in the 2nd quarter valued at approximately $46,000. Finally, SageView Advisory Group LLC bought a new stake in Teladoc Health during the 1st quarter worth approximately $48,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.